Medical Devices

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Brain Cancer Diagnostic Market – Industry Trends and Forecast to 2030

Medical Devices | Published Report | Feb 2023 | MEA | 350 Pages | No of Tables: 65 | No of Figures: 35

Report Description

Middle East and Africa Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography, and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21, 21-34, 35-65 and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Industry Trends and Forecast to 2030.


Middle East and Africa Brain Cancer Diagnostic Market Analysis and Size

One of the primary factors driving the growth of the brain cancer diagnostic market is the rising cases of brain cancer worldwide. The continuing clinical trial research being conducted by several companies for better treatment leads to market expansion. The market is also influenced by rising awareness of the early diagnosis of brain cancer and innovations in drug delivery to brain cancer cells. However, the high cost associated with diagnosis & treatment for brain cancer, late diagnosis of brain cancer resulting in poor prognosis, and side-effects of treatment drugs & therapies acts as a restraining factor for the Middle East and Africa brain cancer diagnostic market in the forecast period.



On the other hand, increasing investments and funding by emerging players, government initiatives towards cancer diagnostics and rising healthcare expenditure act as an opportunity for the growth of the market. However, stringent regulatory requirements for diagnostics products and operational barriers faced in conducting diagnostics tests create challenges for the Middle East and Africa brain cancer diagnostic market.

The demand for brain cancer diagnostics products will increase Middle East and Africa, owing to improved imaging techniques. Various companies are taking initiatives that gradually lead to the growth of the market.

The Middle East and Africa Brain cancer diagnostic market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.9% in the forecast period of 2023 to 2030 and is expected to reach USD 244.87 million by 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2016)

Quantitative Units

Revenue in USD Million

Segments Covered

Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography, and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21, 21-34, 35-65 and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others).

Countries Covered

South Africa, Saudi Arabia, UAE, Egypt, Kuwait, and the rest of the Middle East and Africa

Market Players Covered

Siemens Healthcare GmbH, NIHON KOHDEN CORPORATION., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke, Philips N.V., and BD, among others

Market Definition

Brain cancer is an overgrowth of cells in the brain that forms masses called tumors. It is a brain disorder in which cancer cells (malignant cells) arise in the brain tissue. Cancer cells multiply to produce a mass of cancer tissue (tumor) that interferes with brain functions such as muscle control, sensation, memory, and other body functions. Cancer cells that arise from brain tissue are called primary brain tumors, while tumors that spread from other body parts to the brain are called metastatic or secondary brain tumors.

Primary brain tumors can develop from various brain tissues (for example, glial cells, astrocytes, and other brain cell types). Metastatic brain cancer is caused by the spread of cancer cells from a body organ to the brain.

Middle East and Africa Brain Cancer Diagnostic Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Rising Cases of Brain Cancer Worldwide

Cancer that develops elsewhere in the body & then spreads into the brain is called a secondary brain tumor or brain metastasis. There are various cancers that can metastasize into the brain, such as breast cancer, lung cancer, colon cancer and kidney cancer. Brain cancer cells generally do not spread beyond the brain. Rather, they have the capacity to travel short distances within the brain. Genetic links inherited through family ancestors, chemical exposure to certain industrial chemicals or solvents, compromised immune system, and previous radiation treatments can be some of the major causes of brain cancer.

Brain cancer cases are rising worldwide. In 2019, as per the National Cancer Institute report, there were an estimated 176,566 people found living with brain & other nervous system cancer in the United States. In addition, based on 2017-2019 data, it has been predicted that approximately 0.6 percent of men & women will be diagnosed with brain and other nervous system cancer at some point during their lifetime.

  • Rising awareness of the early diagnosis of brain cancer

Brain cancer awareness month is nationally recognized in the United States during the month of May. This awareness month focuses on bringing together the brain tumor community to increase awareness among the patient population.

Brain cancer is not a common type of cancer like other types. However, the need for new & innovative ways to treat brain cancer is more important. As per research studies, 1.4 million patients worldwide are suffering from malignant brain tumors & another 2, 56,000 people will be diagnosed with a malignant brain tumor by the end of the year.

The importance of patient care, education & cancer research is becoming more apparent due to the impact of COVID-19 worldwide. Considering the future perspectives, there is still more groundwork to be done to discover new drugs & effective approaches for brain cancer patients. Brain cancer awareness month is a movement that is fully dedicated to these efforts and even in the midst of a pandemic.

Opportunities

  • Increasing investment and funding by emerging players

The market for brain cancer is huge, and the rising number of the population affected by this disease is attracting other players to work in the diagnostic field for this disease. Diagnosis of brain cancer in the early stage is a tedious task but can be possible with the new product line for the diagnosis of disease.

The industry offers numerous growth opportunities. Thus, a number of start-ups providing innovative products and technologies have been entering the market. Many new companies and start-ups are looking forward to the field of brain cancer. They are trying to make business expansion and increase the distribution of their newly marketed product. Some of the company are listed below and is expected to act as an opportunity for a brain cancer diagnosis.

  • Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease across the globe. Cancer has increased very briskly in people in past decades. There were 9,555,027 cases of deaths attributable to Middle East and Africa cancers in 2018, of which 241,037 (2.71%) belonged to brain cancers.

The government all around the globe is actively engaged in taking several initiatives towards cancer, specifically brain cancer diagnostics, in order to increase awareness among the people regarding the cancerous disease. Government and Nongovernment organizations funded 57% of therapy-oriented biology and drug development, with 7% to prevention and 13% to early detection, diagnosis and prognosis of cancer disease. These government initiatives towards cancer diagnostics are boosting the demand of the market.

Restraints/Challenges

  • High cost associated with diagnosis & treatment for brain cancer

The brain is the most important part of our body, the organ which generates our memories and emotions, as well as containing our skills and expertise. Therefore, cancer of the brain is uniquely destructive. The changes a brain tumor can cause in cognition, behavior and personality result in high economic costs, which are borne by individuals, health systems (direct medical costs) and the wider public purse (direct non-medical costs and indirect costs).

The average cost of brain tumor surgery in western countries is very high. The costs associated with each type of treatment will vary depending on the specific procedure, location, and tumor severity. A study published in the journal Cancer found that brain cancer patients and their families bore a significantly higher economic burden than those affected by other types of cancer. Brain cancer patients had the highest indirect costs, at an average of USD 64,790 per year. Hence, the high cost associated with the diagnosis & treatment of brain cancer may restrain the market growth.

  • Operational Barriers Faced in Conducting Diagnostics Tests

Recent advances in the field of brain cancer diagnostics may be related to the kits, instruments, reagents, control or any other. It is not easy to change the adaptability of healthcare professionals with advancement. In order to make the structural decisions and précised results in diagnostics, organizations need to conduct a training session for the healthcare professionals to overcome and avoid errors in diagnosis.     

Rural, developing, and low-income countries in the different regions do not have enough infrastructure to maintain the new kits and for the sample storage as well. This is because of the limited supply of electricity and lack and education and awareness among healthcare professionals in the handling of new kits and reagents. This leads to errors in the diagnosis results and can lead to certain deaths, and can become a threat to the carrier of the individual performing the test.

These barriers related to conducting the cancer diagnostics test may affect the life of the populations. This is one of the most difficult parts to overcome with respect to low-income countries. Thus, this is affecting the diagnostics community and acting as a challenge for the Middle East and Africa brain cancer diagnostic market.

Post-COVID-19 Impact on the Middle East and Africa Brain Cancer Diagnostic Market

The COVID-19 pandemic had a great impact on the brain cancer diagnostics and surgical industries. Trade groups in the cancer diagnostic products sector claim that the Middle East and Africa supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the brain cancer diagnostic market. Sales of diagnostics products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care instruments.

The supply of diagnostic products has suffered a massive hit due to the Middle East and Africa pandemic of COVID-19. This reduction in supply is mainly due to various quarantine policies adopted by countries worldwide. This, along with the restrictions of movement and labor reduction, are the major reasons for a decreasing trend in the supply market of diagnostic instrument tracking systems. This has affected the quality and efficacy of medical devices a great deal. The existing product exportation policies of many countries have misbalanced the supply to demand ratio. Reduction in the headcount of the labor force due to COVID-19 affliction is another factor contributing to the reduced supply of brain cancer diagnostics products.

Recent Developments

  • In November 2022, Siemens Healthcare GmbH has presented its two latest magnetic resonance tomographs designed for clinical and scientific use. Due to their high field strengths and strong gradient performance, both scanners will be optimal for detecting the finest structures in the body more clearly.
  • In November 2022, BD has announced to grant USD 652,000 to Valley-Mount Sinai Comprehensive Cancer Care to increase diversity, equity and inclusion in cancer clinical trials.

Middle East and Africa Brain Cancer Diagnostic Market Scope

The Middle East and Africa brain cancer diagnostic market is segmented into test type, cancer type, age group and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Test Type

  • Imaging Tests
  • Biopsy
  • Lumbar Puncture
  • Molecular Testing
  • Electroencephalography (EEG)
  • Others

On the basis of test type, the Middle East and Africa brain cancer diagnostic market is segmented into imaging tests, biopsy, lumber puncture, molecular testing, electroencephalography (EEG), and others.

Cancer Type

  • Acoustic Neuroma
  • Astrocytomas
  • Glioblastoma Multiforme
  • Meningiomas
  • Oligodendroglioma
  • Others

On the basis of cancer type, the Middle East and Africa brain cancer diagnostic market is segmented into acoustic neuroma, astrocytomas, glioblastoma multiforme, meningiomas, oligodendroglioma, and others.

Age Group

  • Below 21
  • 21-35
  • 35-65
  • 65 and above

On the basis of age group, the Middle East and Africa brain cancer diagnostic market is segmented into below 21, 21-34, 35-65 and 65 and above.

End User

On the basis of end user, the Middle East and Africa brain cancer diagnostic market is segmented into hospitals, specialty clinics, diagnostic centers, research institutes, ambulatory surgical centers, and others.


Middle East and Africa Brain Cancer Diagnostic Market Regional Analysis/Insights  

The Middle East and Africa brain cancer diagnostic market is analyzed, and market size insights and trends are provided by country, test type, cancer type, age group, and end user.

The Middle East and Africa brain cancer diagnostic market comprises of South Africa, Saudi Arabia, UAE, Egypt, Kuwait and the rest of the Middle East and Africa.

  • In 2023, South Africa is expected to dominate the Middle East and Africa brain cancer diagnostic market due to increasing awareness among consumers about the benefits of a brain cancer diagnosis. An increase in demand for Brain cancer diagnostics products and an increase in research and development activities in the industry are also expected to drive the market in the forecasted period.

Competitive Landscape and Middle East and Africa Brain Cancer Diagnostic Market Share Analysis

The brain cancer diagnostic market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Middle East and Africa Brain cancer diagnostic market.

Some of the major players operating in this market are NIHON KOHDEN CORPORATION., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke Philips N.V., BD, and FONAR Corp., among others.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT

7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS

7.1 REGULATORY SCENARIO IN THE U.S

7.2 REGULATORY SCENARIO IN AUSTRALIA

7.3 REGULATORY SCENARIO IN JAPAN

7.4 REGULATORY SCENARIO IN CHINA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE

8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER

8.1.3 IMPROVED IMAGING TECHNIQUES

8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER

8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES

8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS

8.3 OPPORTUNITIES

8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS

8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC

8.3.3 RISING HEALTHCARE EXPENDITURE

8.4 CHALLENGES

8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS

8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 CT SCAN

9.2.2 MRI

9.2.3 PET

9.2.4 OTHERS

9.3 MOLECULAR TESTING

9.4 ELECTROENCEPHALOGRAPHY (EEG)

9.5 LUMBAR PUNCTURE

9.6 BIOPSY

9.6.1 OPEN BIOPSY

9.6.2 STEREOTACTIC BIOPSY

9.6.3 NEEDLE BIOPSY

9.6.4 NEUROENDOSCOPY

9.7 OTHERS

10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 GLIOBLASTOMA MULTIFORME

10.3 MENINGIOMAS

10.4 ASTROCYTOMAS

10.5 ACOUSTIC NEUROMA

10.6 OLIGODENDROGLIOMA

10.7 OLIGODENDROGLIOMA

10.8 OTHERS

11 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 35-65

11.3 65 AND ABOVE

11.4 BELOW 21

11.5 21-34

12 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES

12.5 AMBULATORY SURGICAL CENTERS

12.6 OTHERS

13 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E.

13.1.4 KUWAIT

13.1.5 EGYPT

13.1.6 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE

16.1 KONINKLIJKE PHILIPS N.V.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 CANON INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 SIEMENS HEALTHCARE GMBH

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 BD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 NIHON KOHDEN CORPORATION.

16.5.1 COMPANY SNAPSHOT

16.5.2 RECENT FINANCIALS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BIOCEPT, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 BIOMIND

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 CEREBRAL DIAGNOSTIC

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 DXCOVER LIMITED

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 FONAR CORP.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 FUJIFILM CORPORATION

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 GE HEALTHCARE.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 HITACHI, LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 MINFOUND MEDICAL SYSTEMS CO.,

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 NANTOMICS.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 NEUSOFT CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 SEQUOIA HEALTHCARE.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 STERNMED GMBH

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 THERMO FISHER SCIENTIFIC INC.

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TIME MEDICAL HOLDING.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 35 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 36 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 39 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 40 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 41 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 42 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 43 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 45 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 46 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 49 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 51 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 52 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 53 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 57 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 58 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 59 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 63 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 64 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 65 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET

FIGURE 14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022

FIGURE 19 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022

FIGURE 23 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 27 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 31 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

View Infographics

FIGURE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET

FIGURE 14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022

FIGURE 19 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022

FIGURE 23 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 27 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 31 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19